Larvol Delta - Acumen-Pharmaceuticals-to-Present-Sabirnetug-ACU193-Fluid-Biomarker-and-Target-Engagement-Analyses-from-Phase-1-INTERCEPTAD-Study-in-Early-Alzheimers-at-the-ADPD-2024-Annual-Meeting

sabirnetug IV (ACU193 IV) - Acumen Pharma

https://www.globenewswire.com/news-release/2024/02/21/2832702/0/en/Acumen-Pharmaceuticals-to-Present-Sabirnetug-ACU193-Fluid-Biomarker-and-Target-Engagement-Analyses-from-Phase-1-INTERCEPT-AD-Study-in-Early-Alzheimer-s-at-the-AD-PD-2024-Annual-Mee.html

Feb 21, 2024

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next